Home
|
About IAC
|
Contact
|
A-Z Index
|
Donate
|
Shop
|
SUBSCRIBE
Immunization Action Coalition
IAC Home
|
IAC Express
|
2012 Issues
|
Issue 1016
IAC Express: Weekly immunization news and information
IAC Express 1016: September 18, 2012

TOP STORIES

IAC HANDOUTS

JOURNAL ARTICLES AND NEWSLETTERS

EDUCATION AND TRAINING



TOP STORIES

CDC releases provisional ACIP recommendations for PCV13 use in adults with immunocompromising conditions
On September 18, CDC posted ACIP Provisional Recommendations for Use of 13-valent Pneumococcal Conjugate Vaccine in Adults with Immunocompromising Conditions on its website. Most of the content is reprinted below:

On June 20, 2012, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar 13, Pfizer) for adults 19 years and older with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid (CSF) leaks, or cochlear implants (Table 1). PCV13 should be administered to eligible adults in addition to the 23-valent pneumococcal polysaccharide vaccine (PPSV23; Pneumovax, Merck & Co. Inc.), the vaccine recommended for these groups of adults since 1997.

1) Recommendation for the use of PCV13 among pneumococcal vaccine naïve individuals:
  • Adults 19 years of age or older with immunocompromising conditions, functional or anatomic asplenia, CSF leaks, or cochlear implants, and who have not previously received PCV13 or PPSV23, should receive a dose of PCV13 first followed by a dose of PPSV23 at least 8 weeks later (Table 1).
  • Subsequent doses of PPSV23 should follow current PPSV23 recommendations for these adults. Specifically, a second PPSV23 dose is recommended 5 years after the first PPSV23 dose for persons aged 19–64 years with functional or anatomic asplenia and for persons with immunocompromising conditions. Persons with CSF leaks or cochlear implants should receive no additional doses of PPSV23 until age 65 years.
  • Additionally, those who received 1 or 2 doses of PPSV23 before age 65 years for any indication should receive another dose of the vaccine at age 65 years or later if at least 5 years have elapsed since their previous PPSV23 dose.
2) Recommendations for the use of PCV13 among adults who have previously been vaccinated with PPSV23:
  • Adults 19 years of age or older with the aforementioned conditions who have previously received one or more doses of PPSV23 should be given a dose of PCV13 one or more years after the last PPSV23 dose was received. For those who require additional doses of PPSV23 (see Table 1), the first such dose should be given no sooner than 8 weeks after PCV13 and at least 5 years since the most recent dose of PPSV23.
Please see the complete document for references and Table 1, which details medical conditions or other indications for administration of PCV13 as well as indications for PPSV23 administration and revaccination for adults ages 19-64 years.

Back to top


American Academy of Pediatrics releases 2012–13 influenza policy statement
On September 10, the American Academy of Pediatrics (AAP) published Policy Statement: Recommendations for Prevention and Control of Influenza in Children, 2012–2013. The purpose of the statement is to update recommendations for routine use of trivalent seasonal influenza vaccine and antiviral medications for the prevention and treatment of influenza in children. 

Related Links
Back to top


Afghanistan vaccinates over 5.7 million children in combined measles and polio campaign
In July, more than 27,000 healthcare professionals, volunteers, and community mobilizers vaccinated over 5.7 million children against measles and polio in 16 Afghanistan provinces as part of a campaign sponsored by WHO and UNICEF. The government hopes to vaccinate similar numbers in the remaining 18 provinces in the second phase of the campaign, which will start in October.

The Measles & Rubella Initiative posted an article about this vaccination campaign on September 11.

Back to top


Spotlight on immunize.org: IAC's new Apps for Immunization web section
Looking for immunization-related applications (apps) for your mobile device? Look no further. IAC's new Apps for Immunization web section is a listing of free apps related to immunization from trusted sources that are available from iTunes and Google. The apps help make it easy for healthcare professionals to check the latest vaccine recommendations and immunization schedules on their mobile devices, as well as to help parents keep their children up to date on their vaccinations.

Apps for Immunization is the newest addition to IAC’s online Directory of Immunization Resources.

Back to top


IAC HANDOUTS

New staff-education piece: "Influenza Vaccination of People with a History of Egg Allergy" 
IAC recently developed a staff-education sheet titled Influenza Vaccination of People with a History of Egg Allergy. This one-page resource is intended to be a handy way for clinicians to access the current recommendations of the Advisory Committee on Immunization Practices when determining whether or not a person with an egg allergy can receive influenza vaccine.

This new piece is based on the information in Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP) — United States, 2012–13 Influenza Season.

IAC's Handouts for Patients & Staff web section offers healthcare professionals and the public more than 250 FREE English-language handouts (many also available in translation), which we encourage website users to print out, copy, and distribute widely.

Back to top


JOURNAL ARTICLES

CDC reports on 2 cases of avian influenza A (H7N3) virus infection in Mexico 
CDC published Notes from the Field: Highly Pathogenic Avian Influenza A (H7N3) Virus Infection in Two Poultry Workers — Jalisco, Mexico, July 2012 in the September 14 issue of MMWR (pages 726–727). The first and last paragraphs are reprinted below.

During June–August 2012, Mexico's National Service for Health, Safety, and Food Quality reported outbreaks of highly pathogenic avian influenza (HPAI) A (H7N3) virus in poultry on farms throughout the state of Jalisco. This report describes two cases of conjunctivitis without fever or respiratory symptoms caused by HPAI A (H7N3) virus infection in humans associated with exposure to infected poultry....

The conjunctivitis cases in Jalisco most likely represent HPAI A (H7N3) virus transmission from infected poultry to humans through direct contact. United States agricultural, public health, and clinical personnel should be aware of these poultry outbreaks with transmission to humans in a neighboring country. Persons working with poultry known or suspected to be infected with influenza A viruses should use appropriate personal protective equipment, including face masks, gloves and eye protection (e.g., goggles). Clinicians and epidemiologists should consider avian influenza A virus infection in patients who have conjunctivitis or ILI [influenza-like illness] and have contact with poultry in areas with known avian influenza outbreaks. Clinicians who suspect avian influenza A virus infections in humans should obtain a conjunctival or respiratory specimen, or both, depending on signs and symptoms, and submit samples to a national, regional, or state public health laboratory to enable specific influenza testing. Clinicians also should consider early empiric antiviral treatment of suspected cases with a neuraminidase inhibitor. Public health officials should survey family members and contacts of infected persons to find cases of human-to-human transmission. 

Back to top


EDUCATION AND TRAINING

Vaccine Education Center's September 12 webinar rescheduled for October 3
The Vaccine Education Center's September 12 webinar has been rescheduled for October 3 at noon ET.

If you plan to attend the rescheduled event, you do not need to re-register.

If you registered but cannot attend the live event on October 3, you do not have to do anything. The archive of the event will be available to everyone online 24–48 hours later.

More information about the Vaccine Webinar Series

Back to top


Register soon for CDC's September 25 NetConference
CDC will present a Current Issues in Immunization NetConference on September 25 from noon to 1 p.m., ET. Joseph Bresee, MD, FAAP, will present information about influenza A (H3N2) variant virus and pandemic preparedness, and Lisa Grohskopf, MD, MPH, will talk about influenza vaccine and antiviral recommendations. Raymond Strikas, MD, MPH, FACP, will moderate the discussion.

Registration, which is required, will close on September 20 or when the course is full.

Back to top


Clinical Vaccinology course to be held in Miami on November 2–4; early registration ends September 21
CDC published Announcement: Clinical Vaccinology Course — November 2–4, 2012 in the September 14 issue of MMWR. The article announces that CDC and seven other national organizations are collaborating with the National Foundation for Infectious Diseases (NFID), Emory University School of Medicine, and the Emory Vaccine Center to sponsor a Clinical Vaccinology Course to be held November 2–4 in Miami, Florida. The deadline for early registration at a reduced fee is September 21.

Back to top



About IAC Express 
The Immunization Action Coalition welcomes redistribution of this issue of IAC Express or selected articles. When you do so, please add a note that the Immunization Action Coalition is the source of the material and provide a link to this issue.
If you have trouble receiving or displaying IAC Express messages, visit our online help section.
IAC Express is supported in part by Grant No. U38IP000589 from the National Center for Immunization and Respiratory Diseases, CDC. Its contents are solely the responsibility of IAC and do not necessarily represent the official views of CDC. IAC Express is also supported by educational grants from the following companies: Baxter Healthcare Corp.; CSL Biotherapies; GlaxoSmithKline; MedImmune, Inc.; Merck Sharp & Dohme Corp.; Novartis Vaccines; Ortho Clinical Diagnostics, Inc.; Pfizer, Inc.; and sanofi pasteur.
IAC Express Disclaimer
ISSN: 1526-1786

Our mailing address is
Immunization Action Coalition
1573 Selby Ave, Ste 234
St. Paul, MN 55104


Copyright (C) 2012 Immunization Action Coalition
All rights reserved.
Subscribe Today: IAC Express, Needle Tips, and Vaccinate Adults: the up-to-date immunization information you need
IAC Express
IAC Express Home
2014 Issues
2013 Issues
2012 Issues
2011 Issues
2010 - 1997 Issues
Praise for IAC Express
Help
Disclaimer
Video of the Week
Flu.gov Videos
Flu.gov Videos: A series of brief videos offer answers to the following questions about flu. How can I prevent the spread of the flu? What should I do if my child gets the flu? What should I do when caring for someone with the flu? What is the best protection against the flu? What are the symptoms of the flu?
Visit the VOTW archive
Issue Abbreviations
AAFP, American Academy of Family Physicians; AAP, American Academy of Pediatrics; ACIP, Advisory Committee on Immunization Practices; AMA, American Medical Association; CDC, Centers for Disease Control and Prevention; FDA, Food and Drug Administration; IAC, Immunization Action Coalition; MMWR, Morbidity and Mortality Weekly Report; NCIRD, National Center for Immunization and Respiratory Diseases; NIVS, National Influenza Vaccine Summit; VIS, Vaccine Information Statement; VPD, vaccine-preventable disease; WHO, World Health Organization.
Publication Staff
Editor: Deborah L. Wexler, MD
Managing Editor: Dale Thompson, MA
Associate Editor: Teresa Anderson, DDS, MPH
Editorial Assistant: Janelle Tangonan Anderson
Additional Information
News & Information
Media coverage about vaccines and vaccine-preventable diseases
Calendar of Events
Conferences and meetings on immunization
Shop IAC
Record cards, laminated schedules and more
 
This page was reviewed on September 18, 2012
 
Immunization Action Coalition  •  2550 University Avenue West  •  Suite 415 North  •  Saint Paul, Minnesota  •  55114
tel 651-647-9009  •  fax 651-647-9131
 
This website is supported in part by a cooperative agreement from the National Center for Immunization and Respiratory Diseases (Grant No. 5U38IP000290) at the Centers for Disease Control and Prevention (CDC) in Atlanta, GA. The website content is the sole responsibility of IAC and does not necessarily represent the official views of CDC.